

February 2, 2026



# Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care

## *Management to Engage with Global Clinical Research Leaders Ahead of Phase 2a Trial of Concussion Treatment*

Sarasota, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) ("the "Company"), a clinical-stage biotechnology company focused on developing intranasal therapeutics for neurological disorders, today announced its participation at the SCOPE Summit 2026, the 17<sup>th</sup> annual conference organized by the Cambridge Healthtech Institute. SCOPE (Summit for Clinical Ops Executives) is a clinical research conference being held February 2–5, 2026, in Orlando, Florida.

"Oragenics is excited to participate in one of the premier global conferences for clinical operations and optimal trial execution — a timely event as we approach the Phase 2a clinical trial of our first-of-its-kind concussion therapeutic in Australia," said Janet Huffman, Chief Executive Officer. "We look forward to engaging with experts from biopharma, scientific research, and regulatory affairs at SCOPE, especially the technology innovators advancing medical progress and bolstering the body of scientific knowledge."

Oragenics is working towards advancing neurological care through its proprietary intranasal delivery platform designed to enable targeted, non-invasive delivery of therapeutics directly to the brain. Its lead candidate, ONP-002, is advancing toward Phase 2a clinical trials in Australia with the goal of developing it as a treatment for concussion and mild traumatic brain injury—conditions with significant unmet medical need and no FDA-approved therapies.

The SCOPE Summit welcomes senior executives from pharma, biotech, CROs, sites, technology, investment, and patient advocacy organizations, representing over 1,200 companies across 30 countries. The 2026 program will cover in-demand topics like development planning, protocol optimization, patient-centric trial design, site engagement and recruitment, generative AI, small biopharma strategies, RBQM, supply and clintech investment—all focused on advancing solutions in trial planning, operations, innovation, and investment. Visit [scopesummit.com](https://scopesummit.com) for more information.

### **About Oragenics, Inc.**

Oragenics, Inc. is a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology. The Company is working on

advancing its lead candidate, ONP-002, as a potential first-in-class treatment for concussion and mild traumatic brain injury. Oragenics is working on commencing clinical trials in Australia for ONP-002, with U.S. Phase 2b trials planned to follow. The Company's intranasal delivery platform has potential applications across multiple neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders. Oragenics is committed to developing innovative therapies that address significant unmet medical needs in neurological care. For more information, visit [oragenics.com](http://oragenics.com).

## **Forward-Looking Statements**

This communication contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding our future performance, business prospects, expectations and product development plans. These forward-looking statements are not historical facts, but are based on current expectations, estimates and projections about our industry, our beliefs and our assumptions. These forward-looking statements include statements about our strategies, objectives, beliefs, goals, and expectations, including those concerning, among other things, our research, development and regulatory activities, our product development timelines, our future products, regulatory matters, our expectations relating to our products candidates, including ONP-002, the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of concussion and mild traumatic brain injury, and the timing, conduct, interim results announcements and outcomes of our clinical trials of our product candidates, including ONP-002. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project," "potential," "may," "will," "could," "should," and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, those described in our most recent Form 10-K, Form 10-Q and other filings we make with the U.S. Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. All information we set forth in this press release is as of the date hereof. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, except as otherwise required by law.

### **Investor Contact:**

800-383-4880

[ir@oragenics.com](mailto:ir@oragenics.com)



Source: Oragenics, Inc.